LEXXW
Income statement / Annual
Last year (2025), Lexaria Bioscience Corp.'s total revenue was $705.92 K,
an increase of 52.05% from the previous year.
In 2025, Lexaria Bioscience Corp.'s net income was -$11.90 M.
See Lexaria Bioscience Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
08/31/2025 |
08/31/2024 |
08/31/2023 |
08/31/2022 |
08/31/2021 |
08/31/2020 |
08/31/2019 |
08/31/2018 |
08/31/2017 |
08/31/2016 |
| Operating Revenue |
$705.92 K |
$464.28 K |
$226.21 K |
$255.40 K |
$722.74 K |
$314.79 K |
$222.61 K |
$433.29 K |
$63.64 K |
$40.72 K |
| Cost of Revenue |
$2.72 K
|
$4.82 K
|
$31.50 K
|
$71.84 K
|
$175.35 K
|
$99.38 K
|
$22.89 K
|
$25.19 K
|
$29.75 K
|
$45.62 K
|
| Gross Profit |
$703.20 K
|
$459.46 K
|
$194.71 K
|
$183.56 K
|
$547.39 K
|
$215.42 K
|
$199.72 K
|
$408.10 K
|
$33.89 K
|
-$4.90 K
|
| Gross Profit Ratio |
1
|
0.99
|
0.86
|
0.72
|
0.76
|
0.68
|
0.9
|
0.94
|
0.53
|
-0.12
|
| Research and Development Expenses |
$8.24 M
|
$2.36 M
|
$3.67 M
|
$1.84 M
|
$1.26 M
|
$387.07 K
|
$555.73 K
|
$492.86 K
|
$54.19 K
|
$9.02 K
|
| General & Administrative Expenses |
$4.35 M
|
$3.85 M
|
$3.06 M
|
$5.72 M
|
$4.97 M
|
$3.57 M
|
$3.13 M
|
$6.02 M
|
$1.63 M
|
$1.01 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$204.28 K
|
$515.36 K
|
$489.06 K
|
$209.03 K
|
$185.46 K
|
| Selling, General & Administrative Expenses |
$4.35 M
|
$3.85 M
|
$3.06 M
|
$5.72 M
|
$4.97 M
|
$3.77 M
|
$3.64 M
|
$6.51 M
|
$1.84 M
|
$1.20 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$203.52 K
|
$60.55 K
|
$2.31 K
|
-$886.00
|
$4.60 K
|
| Operating Expenses |
$12.58 M
|
$6.21 M
|
$6.73 M
|
$7.57 M
|
$6.23 M
|
$4.36 M
|
$4.26 M
|
$7.01 M
|
$1.90 M
|
$1.21 M
|
| Cost And Expenses |
$12.59 M
|
$6.22 M
|
$6.76 M
|
$6.87 M
|
$6.41 M
|
$4.46 M
|
$4.28 M
|
$7.03 M
|
$1.92 M
|
$1.26 M
|
| Interest Income |
$3.02 K
|
$14.31 K
|
$43.19 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.02 K
|
$2.25 K
|
| Depreciation & Amortization |
$0.00
|
$76.15 K
|
$145.40 K
|
$102.72 K
|
$147.60 K
|
$146.09 K
|
$60.55 K
|
$2.31 K
|
$1.49 K
|
$619.00
|
| EBITDA |
-$11.88 M |
-$5.68 M |
-$6.39 M |
-$6.52 M |
-$5.54 M |
-$4.00 M |
-$4.10 M |
-$6.61 M |
-$1.92 M |
-$1.26 M |
| EBITDA Ratio |
-16.83
|
-12.23
|
-28.24
|
-25.51
|
-7.66
|
-12.72
|
-18.41
|
-15.25
|
-30.2
|
-30.92
|
| Operating Income Ratio |
-16.83
|
-12.39
|
-28.89
|
-25.92
|
-7.87
|
-13.18
|
-17.79
|
-15.23
|
-29.25
|
-29.85
|
| Total Other Income/Expenses Net |
-$21.10 K
|
-$55.52 K
|
-$178.50 K
|
-$764.61 K
|
$1.52 M
|
$0.00
|
-$228.06 K
|
-$8.97 K
|
-$6.02 K
|
-$34.70 K
|
| Income Before Tax |
-$11.90 M
|
-$5.81 M
|
-$6.71 M
|
-$7.38 M
|
-$4.16 M
|
-$4.15 M
|
-$4.16 M
|
-$6.61 M
|
-$1.93 M
|
-$1.28 M
|
| Income Before Tax Ratio |
-16.86
|
-12.51
|
-29.67
|
-28.91
|
-5.76
|
-13.18
|
-18.68
|
-15.25
|
-30.32
|
-31.37
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$39.62 K
|
-$8.97 K
|
-$54.17 K
|
-$60.23 K
|
| Net Income |
-$11.90 M
|
-$5.80 M
|
-$6.66 M
|
-$7.27 M
|
-$4.03 M
|
-$3.93 M
|
-$4.16 M
|
-$6.60 M
|
-$1.87 M
|
-$1.21 M
|
| Net Income Ratio |
-16.86
|
-12.48
|
-29.46
|
-28.46
|
-5.57
|
-12.5
|
-18.68
|
-15.23
|
-29.37
|
-29.83
|
| EPS |
-0.66 |
-0.47 |
-1.01 |
-1.24 |
-0.92 |
-1.42 |
-1.62 |
-2.79 |
-0.95 |
-0.83 |
| EPS Diluted |
-0.66 |
-0.47 |
-1.01 |
-1.24 |
-0.92 |
-1.42 |
-1.62 |
-2.79 |
-0.95 |
-0.83 |
| Weighted Average Shares Out |
$18.00 M
|
$12.38 M
|
$6.61 M
|
$5.89 M
|
$4.39 M
|
$2.77 M
|
$2.59 M
|
$2.37 M
|
$1.96 M
|
$1.46 M
|
| Weighted Average Shares Out Diluted |
$18.00 M
|
$12.38 M
|
$6.61 M
|
$5.89 M
|
$4.39 M
|
$2.77 M
|
$2.59 M
|
$2.37 M
|
$1.96 M
|
$1.46 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
